Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04133376 · ClinicalTrials.gov registry record · NA
Electronic Hookah and Endothelial Cell Function
A NA study of Smoking and Endothelial Dysfunction, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04133376: Completed NA study of Smoking and Endothelial Dysfunction, sponsored by University of California, Los Angeles.
NCT04133376 is a NA study of Smoking and Endothelial Dysfunction that has completed, run by University of California, Los Angeles. The registered enrollment target is 33 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04133376, a NA study of Smoking and Endothelial Dysfunction, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Electronic nicotine delivery systems (ENDS) are a rapidly growing global epidemic among adolescents and young adults. Unlike other ENDS such as e-cigarettes, e-hookahs are used through traditional water-pipes, allowing the vapor-containing nicotine, propylene glycol, glycerin, and flavorings-to pass through a water-filled basin, potentially altering the vapor, before it is inhaled through the user's mouth. Contributing to e-hookahs popularity is the belief that the flavored smoke is detoxified as it passes through the water-filled basin, rendering e-hookah a safer tobacco alternative. However, an e-hookahs deliver flavored nicotine by creating a vapor of fine particles and volatile organic compounds that could induce vascular toxicity. While e-hookah vaping acutely reduces endothelial function, the specific role of nicotine and the mechanisms by which it may impairs endothelial function remain understudied. The objective of this project is to investigate the specific role of nicotine in mediating the acute effects of e-hookah vaping on endothelial dysfunction.
Primary Outcome
Using ultrasound, FMD of the brachial artery induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function. Outcome variable reflecting FMD (brachial artery diameter) was recorded for 45 seconds and resumed 30 seconds before cuff deflation and continuously for 2 minutes after deflation to obtain true peak vasodilatory response.
Conditions Studied
Interventions
- OTHER Electronic hookah vaping with nicotine
- OTHER Electronic hookah vaping without nicotine
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2023-05-29 |
| Phase | NA |
What the finished NCT04133376 record still lists
NCT04133376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Electronic hookah vaping with nicotine is the first listed.
NCT04133376 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04133376 about?
NCT04133376 is a clinical study titled "Electronic Hookah and Endothelial Cell Function". Electronic nicotine delivery systems (ENDS) are a rapidly growing global epidemic among adolescents and young adults. Unlike other ENDS such as e-cigarettes, e-hookahs are used through traditional water-pipes, allowing the vapor-containing nicotine, propylene glycol, glycerin, and flavorings-to pass...
What is the current status of trial NCT04133376?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2020-01-16. Estimated completion is 2023-05-29.
What conditions does trial NCT04133376 study?
This clinical trial studies the following conditions: Smoking, Endothelial Dysfunction.
What interventions are being tested in trial NCT04133376?
The interventions under investigation include: Electronic hookah vaping with nicotine (OTHER), Electronic hookah vaping without nicotine (OTHER).
Who is sponsoring clinical trial NCT04133376?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04133376 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04133376's enrollment target sits among peer trials
33 109th of 123 higher than 15 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Alternatives for Reducing Harm Using E-cigarettes
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
RECRUITING · NA
-
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
RECRUITING · NA
-
Take A Break - Rural
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI